Navellier & Associates Inc. Invests $368,000 in Electromed, Inc. (NYSE:ELMD)

Navellier & Associates Inc. acquired a new position in Electromed, Inc. (NYSE:ELMD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 17,160 shares of the company’s stock, valued at approximately $368,000. Navellier & Associates Inc. owned about 0.20% of Electromed as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ELMD. Morgan Dempsey Capital Management LLC purchased a new stake in shares of Electromed during the second quarter worth $108,000. Marshall Wace LLP purchased a new stake in Electromed during the 2nd quarter worth about $256,000. Pekin Hardy Strauss Inc. bought a new position in Electromed in the 2nd quarter worth about $522,000. Gabelli Funds LLC grew its holdings in Electromed by 76.1% during the 1st quarter. Gabelli Funds LLC now owns 35,867 shares of the company’s stock valued at $579,000 after buying an additional 15,500 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Electromed by 4.8% during the second quarter. Renaissance Technologies LLC now owns 103,004 shares of the company’s stock valued at $1,548,000 after acquiring an additional 4,736 shares in the last quarter. 40.82% of the stock is currently owned by institutional investors.

Electromed Price Performance

NYSE ELMD opened at $29.77 on Friday. The company’s 50 day simple moving average is $23.00 and its two-hundred day simple moving average is $18.11. Electromed, Inc. has a 1 year low of $9.81 and a 1 year high of $30.00. The stock has a market capitalization of $251.79 million, a PE ratio of 38.99 and a beta of 0.27.

Electromed (NYSE:ELMD) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.13. The firm had revenue of $14.67 million during the quarter. Electromed had a return on equity of 15.32% and a net margin of 11.34%.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.